Marshall Wace
BSTC

Marshall Wace’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Marshall Wace’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,447
Closed -$766K – 2255
2019
Q4 		$766K Sell
13,447
-3,439
-20% -$182K 0.01% 1047
2019
Q3 		$904K Buy
+16,886
New +$983K 0.01% 968

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Marshall Wace's BSTC Position: Q1 2020 in Review

Marshall Wace sold out of BioSpecifics Technologies Corp. (BSTC) in Q1 2020, closing a stake of 13,447 shares — an estimated $766K sold.

Marshall Wace first reported a position in BSTC in Q3 2019 and held it in 2 quarters. The position peaked at $904K in Q3 2019. 113 funds tracked by Wall St. Rank hold BSTC as of Q1 2020.

  • Marshall Wace reported no remaining BioSpecifics Technologies Corp. position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace sold 13,447 BioSpecifics Technologies Corp. shares in Q1 2020, an estimated $766K.
  • Marshall Wace first reported a position in BioSpecifics Technologies Corp. in Q3 2019 and held it in 2 quarters.
  • Marshall Wace's BioSpecifics Technologies Corp. position peaked at $904K in Q3 2019.
  • 113 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q1 2020.

Based on Marshall Wace's 13F filing for Q1 2020, filed 15 May 2020.